Newsletter January 2022

We propose a condensate of ImaBiotech Group’s updates, activities and publications on a quarterly manner. We are proud to be an active global bioanalytical CRO, providing a unique set of services spanning the drug development cycle, from early-stage discovery through Phase IV.

In this last quarterly release of 2021, we are happy to share ImaBiotech’s celebration with Fluidigm on their achievement of #100 publications on the unique & robust high multiplex IHC imaging. ImaBiotech initiated a collaboration and comarketing agreement with Fluidigm Corporation in 2021 for service offerings and product development for Imaging Mass Cytometry™ (IMC™).

During the last quarter, ImaBiotech released two White Papers where one of them elucidates the immunologic alterations in the lung cancer environment of patients treated with immune checkpoint inhibitor, and the other demonstrates the use of quantitative image analysis based on multiplexed immunohistochemistry and deep learning technologies, to interrogate complex information from the tumor microenvironment and find predictive insights into treatment response for non small cell lung cancer.

ImaBiotech also released a publication in collaboration with Genoscience on how GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular 2 carcinoma via modulation of lysosomal functions. A new book chapter “Quantitative MSI: A Review of Biomarker and Drug Quantifications Using Mass Spectrometry Imaging” authored by the CEO of ImaBiotech Group, Jonathan Stauber & Tiffany Siegel, Scientist – Mass Spectrometry Imaging at Boehringer Ingelheim was also released during the last quarter of 2021.

Two webinars, one hosted by our Innovation Director, Corinne Ramos and other by our Data Scientist, Amandine Gerstenberg were conducted to illustrate the use of Fluidigm’s Hyperion (Imaging Mass Cytometry) platform, combined with image analysis to optimize drug development.

In this edition, we have also shared information on an interview given by Corinne Ramos to Fluidigm where she explained how ImaBiotech performs a complete progression of the drug development pipeline from biomarker identification & assessment of cell behavior to drug safety & movement to clinical trials.

You will also discover ImaBiotech’s services for digital pathology, spatially resolved gene expression & mass spectrometry imaging for drug development and biomarker discovery. You will be able to access all the white papers, publication and application note on our website’s dedicated Resources section.

Follow us on or www.linkedin/imabiotech

Discover our Videos on Youtube/ImaBiotech

Search news